サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514001

H1N1ワクチンの世界市場

H1N1 Vaccines

出版日
ページ情報
英文 268 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
H1N1ワクチンの世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 268 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

H1N1ワクチンの世界市場は2030年までに32億米ドルに達する

2023年に22億米ドルと推定されるH1N1ワクチンの世界市場は、分析期間2023-2030年にCAGR 5.4%で成長し、2030年には32億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである筋肉内ワクチンは、CAGR 6.5%を記録し、分析期間終了時には11億米ドルに達すると予測されます。経鼻ワクチン分野の成長率は、分析期間中CAGR 5.6%と推定されます。

米国市場は5億7,260万米ドルと推定、中国はCAGR 8.5％で成長予測

米国のH1N1ワクチン市場は、2023年に5億7,260万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億3,450万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.0％と4.3％と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

H1N1ワクチン-主要動向と促進要因

H1N1ワクチンは、一般に豚インフルエンザとして知られるH1N1インフルエンザウイルスの蔓延を防ぐ上で極めて重要です。H1N1ウイルスは2009年に初めて出現し、世界的大流行を引き起こし、効果的なワクチン戦略の必要性を浮き彫りにしました。これらのワクチンは、不活化（死滅）ウイルス、弱毒化（生）ウイルス、組み換え技術など、さまざまな方法で開発されています。これらのワクチンは、免疫系を刺激してH1N1ウイルスを認識させ、闘わせることで、病気の重症度と発症率を下げるように設計されています。特にインフルエンザの流行期には、小児、高齢者、妊娠中の女性、基礎疾患を持つ人など、リスクの高いグループを対象に、毎年ワクチン接種キャンペーンを実施し、公衆衛生上の重要な役割を果たしています。ウイルスの継続的な進化により、新型に対するワクチンの有効性を確保するために、ワクチン製剤の継続的な更新と改良が必要となっています。

技術の進歩は、H1N1ワクチンの開発、製造、流通を著しく向上させました。細胞ベース技術や組換えDNA技術を含む最新の製造技術は、ワクチン製造の効率とスピードを向上させました。これらの方法により、アウトブレイクに対応した迅速なスケーラビリティが可能になり、世界の需要を満たす十分な供給が確保されるようになった。さらに、免疫反応を高めるためにワクチンに添加される物質であるアジュバント技術の進歩により、H1N1ワクチンの有効性が向上しています。サーベイランスシステムの強化と保健機関間の世界な連携により、ウイルス変異のタイムリーな特定が容易になり、最新のワクチンの開発が可能になった。さらに、電子カルテ（EHR）やモバイルヘルスアプリなどのデジタルヘルスツールの統合は、ワクチン接種プログラムの効果的なモニタリングと管理をサポートし、より高い接種率とワクチンの有効性のより良い追跡を保証します。

H1N1ワクチン市場の成長は、ワクチン接種の重要性に対する意識の高まり、政府の取り組みや資金提供、ワクチン開発における技術進歩など、いくつかの要因によってもたらされます。ワクチン接種の利点を強調する公衆衛生キャンペーンは、ワクチン摂取を大幅に増加させています。ワクチンの研究開発および流通に資金や資源を提供する政府のプログラムや政策も、市場成長において極めて重要な役割を果たしています。バイオテクノロジーと免疫学の技術的進歩により、より効果的で安全なワクチンが開発されています。さらに、インフルエンザ流行の増加とH1N1ウイルスの継続的な変異が、継続的なワクチン接種の必要性を高めています。製薬会社と研究機関の協力により、ワクチンの革新と入手が加速しています。世界のヘルスケア・インフラの拡大とコールドチェーン物流の改善は、H1N1ワクチンの広範な配布と入手可能性をさらに後押ししています。全体として、これらの要因がH1N1ワクチン市場の堅調な成長と開拓に寄与しています。

調査対象企業の例（注目の33社）

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6274

Global H1N1 Vaccines Market to Reach US$3.2 Billion by 2030

The global market for H1N1 Vaccines estimated at US$2.2 Billion in the year 2023, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Intramuscular Vaccines, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Intranasal Vaccines segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$572.6 Million While China is Forecast to Grow at 8.5% CAGR

The H1N1 Vaccines market in the U.S. is estimated at US$572.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$734.5 Million by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

H1N1 Vaccines - Key Trends and Drivers

H1N1 vaccines are critical in preventing the spread of the H1N1 influenza virus, commonly known as swine flu. The H1N1 virus first emerged in 2009, causing a global pandemic that highlighted the need for effective vaccination strategies. These vaccines are developed using various methods, including inactivated (killed) virus, live attenuated (weakened) virus, and recombinant technologies. They are designed to stimulate the immune system to recognize and combat the H1N1 virus, thereby reducing the severity and incidence of the disease. Annual vaccination campaigns, particularly during flu season, play a crucial role in public health initiatives, targeting high-risk groups such as children, the elderly, pregnant women, and individuals with underlying health conditions. The ongoing evolution of the virus necessitates continuous updates and improvements in vaccine formulations to ensure their effectiveness against new strains.

Technological advancements have significantly enhanced the development, production, and distribution of H1N1 vaccines. Modern manufacturing techniques, including cell-based and recombinant DNA technologies, have improved the efficiency and speed of vaccine production. These methods allow for rapid scalability in response to outbreaks, ensuring sufficient supply to meet global demand. Additionally, advancements in adjuvant technology, which are substances added to vaccines to boost the immune response, have improved the efficacy of H1N1 vaccines. Enhanced surveillance systems and global collaboration among health organizations facilitate the timely identification of viral mutations, enabling the development of updated vaccines. Moreover, the integration of digital health tools, such as electronic health records (EHRs) and mobile health apps, supports effective monitoring and management of vaccination programs, ensuring higher coverage rates and better tracking of vaccine efficacy.

The growth in the H1N1 vaccines market is driven by several factors, including increasing awareness of the importance of vaccination, government initiatives and funding, and technological advancements in vaccine development. Public health campaigns emphasizing the benefits of vaccination have significantly increased vaccine uptake. Government programs and policies that provide funding and resources for vaccine research, development, and distribution also play a pivotal role in market growth. Technological advancements in biotechnology and immunology have led to the development of more effective and safer vaccines. Additionally, the rising prevalence of influenza outbreaks and the continuous mutation of the H1N1 virus drive the need for ongoing vaccination efforts. Collaboration between pharmaceutical companies and research institutions accelerates the innovation and availability of vaccines. The expansion of global healthcare infrastructure and improvements in cold chain logistics further support the widespread distribution and accessibility of H1N1 vaccines. Overall, these factors collectively contribute to the robust growth and development of the H1N1 vaccines market.

Select Competitors (Total 33 Featured) -

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • H1N1 Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Vaccination Importance Throws the Spotlight on H1N1 Vaccines
    • Government Initiatives and Funding Propel Growth in Vaccine Research and Development
    • Technological Advancements in Biotechnology Expands Addressable Market Opportunity
    • Enhanced Surveillance Systems Strengthens Business Case for Timely Vaccine Updates
    • Integration of Adjuvant Technology Generates Demand for More Effective Vaccines
    • Development of Cell-Based and Recombinant DNA Technologies Drives Adoption of Modern Manufacturing Methods
    • Increasing Influenza Outbreaks and Viral Mutations Accelerates Demand for H1N1 Vaccines
    • Digital Health Tools and EHRs Spur Growth in Vaccination Program Management
    • Improvements in Cold Chain Logistics Sustains Growth in Vaccine Accessibility
    • Public Health Campaigns and Education Programs Generates Awareness and Vaccine Uptake
    • Ongoing Research in Immunology and Virology Expands Addressable Market Opportunity for Advanced Vaccines
    • Impact of Seasonal Variability on Vaccination Needs
    • Safety and Efficacy Improvements in Vaccine Formulations Drives Adoption of New Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World H1N1 Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Intranasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Intranasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Inactivated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 18: USA Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • JAPAN
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Japan 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • CHINA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 24: China Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: China 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • EUROPE
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 28: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Europe 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • FRANCE
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 30: France Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: France 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • GERMANY
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • ITALY
    • TABLE 34: Italy Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Italy 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • UNITED KINGDOM
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 36: UK Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: UK 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • SPAIN
    • TABLE 38: Spain Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Spain 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • RUSSIA
    • TABLE 40: Russia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: Russia 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 42: Rest of Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Rest of Europe 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • ASIA-PACIFIC
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2024 & 2030
    • TABLE 46: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Asia-Pacific 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • AUSTRALIA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 48: Australia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Australia 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • INDIA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 50: India Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: India 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • SOUTH KOREA
    • TABLE 52: South Korea Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: South Korea 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 54: Rest of Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Rest of Asia-Pacific 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • LATIN AMERICA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 56: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 57: Latin America 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2024 & 2030
    • TABLE 58: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Latin America 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • ARGENTINA
    • TABLE 60: Argentina Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Argentina 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • BRAZIL
    • TABLE 62: Brazil Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Brazil 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • MEXICO
    • TABLE 64: Mexico Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Mexico 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 66: Rest of Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Rest of Latin America 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • MIDDLE EAST
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 68: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Middle East 7-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2024 & 2030
    • TABLE 70: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: Middle East 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • IRAN
    • TABLE 72: Iran Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: Iran 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • ISRAEL
    • TABLE 74: Israel Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Israel 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • SAUDI ARABIA
    • TABLE 76: Saudi Arabia Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Saudi Arabia 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 78: UAE Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: UAE 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 80: Rest of Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Middle East 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030
  • AFRICA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 82: Africa Recent Past, Current & Future Analysis for H1N1 Vaccines by Type - Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Africa 7-Year Perspective for H1N1 Vaccines by Type - Percentage Breakdown of Value Sales for Intramuscular, Intranasal, Conjugate, Attenuated Vaccines, Inactivated Vaccine, Toxoid and Other Vaccine Types for the Years 2024 & 2030

IV. COMPETITION